{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:12255"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:12255","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Characterisation of platelet receptor CLEC-2 in thrombosis and inflammation","abstract":"Platelets have an established role in thrombosis and haemostasis. C-type lectin-like receptor 2 (CLEC-2) is highly expressed on platelets and a subpopulation of myeloid cells, and is critical in lymphatic development. Using a recently developed mouse model for platelet-specific deletion of platelet-CLEC-2, CLEC1bfl/flGPIb-Cre, we show that CLEC-2 contributes to thrombus stability in mice. However, CLEC-2 inhibition in human blood using monoclonal antibody, AYP1, or recombinant CLEC-2 did not translate these observations to human. This presents CLEC-2 as a promising therapeutic target in thromboinflammatory or inflammatory disease, without detriment to thrombosis and haemostasis. We show that hemin, the oxidised form of haem released post-haemolysis, is a novel CLEC-2 ligand which can activate and aggregate platelets through its hemITAM domain. Interestingly, anti-malarial drug hydroxychloroquine is able to inhibit hemin-induced mouse and human platelet activation, but not ROS generation. In a mouse model of thrombosis, the ferric chloride injury of the carotid artery, we demonstrate that hydroxychloroquine treatment presents small, non-occlusive thrombi, compared to saline-treated controls. This may present hemin-CLEC-2 as a promising therapeutic target in thromboinflammatory disease. Beyond thrombosis, platelets contribute to the development, progression and resolution of the inflammatory response. CLEC-2 is protective during mouse models of sepsis, and other inflammatory diseases. Here we show that CLEC-2 reduces tissue inflammation by regulating inflammatory macrophage activation and trafficking from inflamed tissue during murine peritonitis through its ligand, podoplanin. Treatment using recombinant CLEC-2-Fc induces the rapid emigration of peritoneal inflammatory macrophages to mesenteric lymph nodes, thus reducing the accumulation of inflammatory macrophages in the inflamed peritoneum. Macrophage efflux to draining lymph nodes induces T cell priming. In conclusion, we show that CLEC-2 reduces the inflammatory phenotype of macrophages and their accumulation, leading to diminished tissue inflammation. Both the thromboinflammatory and immunomodulatory functions of CLEC-2 present strategies to reduce tissue inflammation and inflammatory thrombi, and could be therapeutically exploited to limit disease progression.","abstract_html":"Platelets have an established role in thrombosis and haemostasis. C-type lectin-like receptor 2 (CLEC-2) is highly expressed on platelets and a subpopulation of myeloid cells, and is critical in lymphatic development. Using a recently developed mouse model for platelet-specific deletion of platelet-CLEC-2, CLEC1bfl/flGPIb-Cre, we show that CLEC-2 contributes to thrombus stability in mice. However, CLEC-2 inhibition in human blood using monoclonal antibody, AYP1, or recombinant CLEC-2 did not translate these observations to human. This presents CLEC-2 as a promising therapeutic target in thromboinflammatory or inflammatory disease, without detriment to thrombosis and haemostasis. We show that hemin, the oxidised form of haem released post-haemolysis, is a novel CLEC-2 ligand which can activate and aggregate platelets through its hemITAM domain. Interestingly, anti-malarial drug hydroxychloroquine is able to inhibit hemin-induced mouse and human platelet activation, but not ROS generation. In a mouse model of thrombosis, the ferric chloride injury of the carotid artery, we demonstrate that hydroxychloroquine treatment presents small, non-occlusive thrombi, compared to saline-treated controls. This may present hemin-CLEC-2 as a promising therapeutic target in thromboinflammatory disease. Beyond thrombosis, platelets contribute to the development, progression and resolution of the inflammatory response. CLEC-2 is protective during mouse models of sepsis, and other inflammatory diseases. Here we show that CLEC-2 reduces tissue inflammation by regulating inflammatory macrophage activation and trafficking from inflamed tissue during murine peritonitis through its ligand, podoplanin. Treatment using recombinant CLEC-2-Fc induces the rapid emigration of peritoneal inflammatory macrophages to mesenteric lymph nodes, thus reducing the accumulation of inflammatory macrophages in the inflamed peritoneum. Macrophage efflux to draining lymph nodes induces T cell priming. In conclusion, we show that CLEC-2 reduces the inflammatory phenotype of macrophages and their accumulation, leading to diminished tissue inflammation. Both the thromboinflammatory and immunomodulatory functions of CLEC-2 present strategies to reduce tissue inflammation and inflammatory thrombi, and could be therapeutically exploited to limit disease progression.","abstract_has_math":false,"creators":["Bourne, Joshua Henry"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-12","date_published":"2022-12","updated_at":"2026-11-19T09:31:41Z","subjects":["QP Physiology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000344425767"],"render_values":[{"text":"0000-0003-4442-5767","href":"https://orcid.org/0000-0003-4442-5767","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/12255/7/Bourne2022PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A12255","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Bourne, Joshua Henry"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000344425767"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-12"]},{"key":"dc:date.issued","label":"Date","values":["2022-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cardiovascular Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/12255/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QP Physiology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/12255/7/Bourne2022PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Platelets have an established role in thrombosis and haemostasis. C-type lectin-like receptor 2 (CLEC-2) is highly expressed on platelets and a subpopulation of myeloid cells, and is critical in lymphatic development. Using a recently developed mouse model for platelet-specific deletion of platelet-CLEC-2, CLEC1bfl/flGPIb-Cre, we show that CLEC-2 contributes to thrombus stability in mice. However, CLEC-2 inhibition in human blood using monoclonal antibody, AYP1, or recombinant CLEC-2 did not translate these observations to human. This presents CLEC-2 as a promising therapeutic target in thromboinflammatory or inflammatory disease, without detriment to thrombosis and haemostasis. We show that hemin, the oxidised form of haem released post-haemolysis, is a novel CLEC-2 ligand which can activate and aggregate platelets through its hemITAM domain. Interestingly, anti-malarial drug hydroxychloroquine is able to inhibit hemin-induced mouse and human platelet activation, but not ROS generation. In a mouse model of thrombosis, the ferric chloride injury of the carotid artery, we demonstrate that hydroxychloroquine treatment presents small, non-occlusive thrombi, compared to saline-treated controls. This may present hemin-CLEC-2 as a promising therapeutic target in thromboinflammatory disease. Beyond thrombosis, platelets contribute to the development, progression and resolution of the inflammatory response. CLEC-2 is protective during mouse models of sepsis, and other inflammatory diseases. Here we show that CLEC-2 reduces tissue inflammation by regulating inflammatory macrophage activation and trafficking from inflamed tissue during murine peritonitis through its ligand, podoplanin. Treatment using recombinant CLEC-2-Fc induces the rapid emigration of peritoneal inflammatory macrophages to mesenteric lymph nodes, thus reducing the accumulation of inflammatory macrophages in the inflamed peritoneum. Macrophage efflux to draining lymph nodes induces T cell priming. In conclusion, we show that CLEC-2 reduces the inflammatory phenotype of macrophages and their accumulation, leading to diminished tissue inflammation. Both the thromboinflammatory and immunomodulatory functions of CLEC-2 present strategies to reduce tissue inflammation and inflammatory thrombi, and could be therapeutically exploited to limit disease progression."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Characterisation of platelet receptor CLEC-2 in thrombosis and inflammation"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Bourne, Joshua Henry"],"dc:date":["2022-12"],"dc:date.issued":["2022-12"],"dc:description.abstract":["Platelets have an established role in thrombosis and haemostasis. C-type lectin-like receptor 2 (CLEC-2) is highly expressed on platelets and a subpopulation of myeloid cells, and is critical in lymphatic development. Using a recently developed mouse model for platelet-specific deletion of platelet-CLEC-2, CLEC1bfl/flGPIb-Cre, we show that CLEC-2 contributes to thrombus stability in mice. However, CLEC-2 inhibition in human blood using monoclonal antibody, AYP1, or recombinant CLEC-2 did not translate these observations to human. This presents CLEC-2 as a promising therapeutic target in thromboinflammatory or inflammatory disease, without detriment to thrombosis and haemostasis. We show that hemin, the oxidised form of haem released post-haemolysis, is a novel CLEC-2 ligand which can activate and aggregate platelets through its hemITAM domain. Interestingly, anti-malarial drug hydroxychloroquine is able to inhibit hemin-induced mouse and human platelet activation, but not ROS generation. In a mouse model of thrombosis, the ferric chloride injury of the carotid artery, we demonstrate that hydroxychloroquine treatment presents small, non-occlusive thrombi, compared to saline-treated controls. This may present hemin-CLEC-2 as a promising therapeutic target in thromboinflammatory disease. Beyond thrombosis, platelets contribute to the development, progression and resolution of the inflammatory response. CLEC-2 is protective during mouse models of sepsis, and other inflammatory diseases. Here we show that CLEC-2 reduces tissue inflammation by regulating inflammatory macrophage activation and trafficking from inflamed tissue during murine peritonitis through its ligand, podoplanin. Treatment using recombinant CLEC-2-Fc induces the rapid emigration of peritoneal inflammatory macrophages to mesenteric lymph nodes, thus reducing the accumulation of inflammatory macrophages in the inflamed peritoneum. Macrophage efflux to draining lymph nodes induces T cell priming. In conclusion, we show that CLEC-2 reduces the inflammatory phenotype of macrophages and their accumulation, leading to diminished tissue inflammation. Both the thromboinflammatory and immunomodulatory functions of CLEC-2 present strategies to reduce tissue inflammation and inflammatory thrombi, and could be therapeutically exploited to limit disease progression."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/12255/7/Bourne2022PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cardiovascular Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/12255/"],"dc:subject":["QP Physiology"],"dcterms:accessrights":["public"],"dc:title":["Characterisation of platelet receptor CLEC-2 in thrombosis and inflammation"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"],"person:identifier.orcid":["0000000344425767"]},"updated_at":"2026-11-19T09:31:41Z"}